Ultomiris® (ravulizumab-cwvz) – New formulation approval
July 22, 2022 - The FDA approved a subcutaneous (SC) formulation of Alexion Pharmaceuticals’ Ultomiris (ravulizumab-cwvz), for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Top